RDY FY 2016 Earnings Report — Dr. Reddy's Laboratories Limited Revenue & Financial Results | Market Cap Arena

Dr. Reddy's Laboratories LimitedRDY

FY 2016 Earnings

Reported June 23, 2016

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2016	Prior Q	FY 2015	QoQ Change	YoY Change
Revenue	$1.6B	—	$1.6B	—	4.4%
Op. Income	$315M	—	$279M	—	12.7%
Gross Margin	59.6%	—	57.6%	—	2.0pp
Net Margin	12.9%	—	15.0%	—	-2.0pp
EPS (Diluted)	$1.24	—	$1.38	—	-9.8%
Free Cash Flow	$280M	—	$103M	—	171.7%

Revenue Flow

Item	Amount
REVENUE	$1.6B
Cost of Revenue	$663M
GROSS PROFIT	$980M
R&D Expenses	$189M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$485M
Other Expenses	-$10M
Operating Expenses	$665M
Cost & Expenses	$1.3B
OPERATING INCOME	$315M
Interest Income	$15M
Interest Expense	$9M
Other Income/Expenses	-$26M
INCOME BEFORE TAX	$288M
Income Tax Expense	$76M
Net Income from Continuing Ops	$213M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$213M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$213M
D&A	$109M
EBIT	$297M
EBITDA	$427M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$1.6B
Cost of Revenue	$663M
GROSS PROFIT	$980M
R&D Expenses	$189M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$485M
Other Expenses	-$10M
Operating Expenses	$665M
Cost & Expenses	$1.3B
OPERATING INCOME	$315M
Interest Income	$15M
Interest Expense	$9M
Other Income/Expenses	-$26M
INCOME BEFORE TAX	$288M
Income Tax Expense	$76M
Net Income from Continuing Ops	$213M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$213M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$213M
D&A	$109M
EBIT	$297M
EBITDA	$427M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$213M
Depreciation & Amortization	$109M
Stock-Based Compensation	$5M
Deferred Income Tax	$76M
Other Non-Cash Items	$38M
Change in Working Capital	-$2M
OPERATING CASH FLOW	$438M
Capital Expenditure	-$158M
Acquisitions (Net)	-$84M
Purchases of Investments	-$725M
Sales/Maturities of Investments	$736M
Other Investing Activities	$15M
NET CASH FROM INVESTING	-$217M
Net Debt Issuance	-$127M
Common Stock Repurchased	$0
Common Dividends Paid	-$44M
Other Financing Activities	-$17M
NET CASH FROM FINANCING	-$181M
FREE CASH FLOW	$280M
Net Change in Cash	-$5M

Balance Sheet

Item	Amount
Cash & Equivalents	$424M
Short-Term Investments	$0
Net Receivables	$516M
Inventory	$272M
Other Current Assets	$129M
TOTAL CURRENT ASSETS	$1.3B
PP&E (Net)	$573M
Goodwill	$41M
Intangible Assets	$221M
Long-Term Investments	$35M
Tax Assets	$53M
Other Non-Current Assets	$11M
TOTAL NON-CURRENT ASSETS	$934M
TOTAL ASSETS	$2.2B
Account Payables	$0
Short-Term Debt	$241M
Deferred Revenue	$7M
Other Current Liabilities	$116M
TOTAL CURRENT LIABILITIES	$686M
Long-Term Debt	$106M
Deferred Revenue NC	$16M
Deferred Tax Liabilities	$8M
Other Non-Current Liabilities	$42M
TOTAL NON-CURRENT LIABILITIES	$156M
TOTAL LIABILITIES	$842M
Common Stock	$9M
Additional Paid-In Capital	$240M
Retained Earnings	$1.1B
Treasury Stock	$0
Accum. Other Comp. Income	$57M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$1.4B
Minority Interest	$0
TOTAL EQUITY	$1.4B
TOTAL LIABILITIES & EQUITY	$2.2B
Total Debt	$356M
Net Debt	-$68M